valu usd unless otherwis note
oper beat fuel healthi organ growth expect
guidanc trim reflect dental ipo increment
headwind fx tariff deal rebrand
cytiva track close estim accret trued-
small life scienc divestitur lower financ cost
trim guidanc envista minor interest higher fx tariff
headwind report modest oper beat driven
healthi organ growth ex-dent upsid life scienc
diagnost offset modest shortfal product id expect
slightli lower cash ep guidanc
midpoint reflect minor interest envista
ipo also increment fx
tariff headwind off-set flow-through
oper upsid higher net interest incom
would attribut modest under-perform share
vs peer guidanc cut prospect slight
organ revenu deceler said continu
view attract high-qual defens name
rel insul short-cycl industri macro slowdown
reiter cash ep estim price target
growth key life scienc diagnost busi radiomet
leica biosystem double-digit thank demand pull-in
ahead new japan vat went effect similarli pall
biotech revenu double-digit quarter due earlier-
than-expect shipment larg equip order result danah
expect modest step-down organ growth
though note organ growth roughli
consist two-year stack
implications/read-across ge biopharma accret tru closer
deal complet date previous estim ge
biopharma rebrand cytiva would gener
cash ep said estim like affect lower-
than-expect financ cost recently-announc small life scienc
divestitur made help secur anti-trust approv danah plan
wait closer deal expect complet
provid updat accret forecast
valuat near high-end rang trade premium
peer ep vs target rang price target
assum trade premium target group multipl
price prior trade day market close estimate unless otherwis note
best-in-class multi-industri name metric
hold much-covet posit among higher
qualiti prime coverag accord
sector-best consecut year
know-how rever danah busi system
posit includ recur revenu market
leadership across portfolio
acquir biopharma busi bil
announc acquir biopharma
busi bil impli reason deal multipl
ev/ebitda deal expect produc mil
cost save roughli
cash ep accret ge biopharma lead provid
instrument consum softwar support
research discoveri process develop manufactur
workflow biopharmaceut drug
like pursu orderli stage exit remain
ownership dental complet
ipo dental busi name envista
ticker mil net proce manag
primari rational separ dental view
flexibl organ inorgan invest
includ stand-alone compani recal
argument led compani spin-off
industri busi expect
exit remain ownership envista
either futur spin secondari offer
given expens price-tag below-benchmark
expect return major integr stumbl ge
biopharma pall cepheid would damag faith
investor disciplin
bloomberg capit market estim upside/downside/target
given portfolio migrat toward higher-tech life scienc
busi believ re-rat toward
target rel price-to-earnings premium rang believ
trade high-end rang
due solid outlook investor enthusiasm
pend acquisit premium
target group multipl price-to-earnings
ep cash ep impli valuat
support sector perform rate
market enter risk-off environ danah
deliv upsid synergies/accret target
believ stock may abl re-rat beyond high-
end rel rang premium
target group multipl adjust ep also see
potenti upsid ep cash ep reach
level includ acceler organ growth end
carri execut risk misstep
 integr could weigh stock addit
high-qual defens name would lag
market enter prolong risk-on environ favor
cyclic higher-beta stock could see price-to-earnings contract
premium peer midpoint
target rel rang also risk end
market slowdown result ep cash ep closer
valuat
takeaway result
revenu high growth
market high-
single-digit led high-
single-digit china
double-digit russia
develop market
mid-single-digit led
cash ep narrowli beat estim consensu driven upsid
oper line report cash ep beat estim
consensu high-end guidanc organ revenu growth
slightli ahead forecast guidanc upsid life
scienc diagnost offset slight shortfal dental environment appli
solut exclud dental busi organ revenu total compani
adjust oper margin expand bp y/i bp ahead estim
increment margin solid quarter overal oper line beat
estim compris life scienc diagnost dental
environment appli solut line minor interest envista ipo
includ forecast quarter shave ep partli
off-set upsid lower tax rate final free cash flow convers
quarter touch light vs histor averag
capit market compani report note organ revenu growth estim sector actual
trim cash ep guidanc midpoint reflect dental ipo
increment fx tariff pressur expect lower cash ep guidanc
rang move midpoint new
high-end fell short consensu time releas believ
fulli adjust envista ipo said sever put take
guidanc revis bridg includ minor interest envista
ipo consist estim howev also includ
project increment fx tariff headwind compris fx
tariff mostli off-set flow oper upsid vs
manag expect along increment net interest incom expect
maintain cash ep estim
cash ep guidanc rang fell short consensu note
consensu appear account minor interest
envista land organ revenu growth exclud dental expect
deceler though increment margin remain healthi
growth step-down attribut time dynam includ
larg pall equip order ship impact japan tax
regul went effect result demand pull-in radiomet
leica biosystem trim cash ep estim
organ growthshad area multi-industri sector averagenot restatedfor spin electr equip multi-industri
exhibit danah earn guidanc vs estim consensu
life scienc sale organ revenu led double-digit growth
beckman life scienc across major geograph region thank new product
launch said sciex organ revenu slightli tough y/i comp
growth meanwhil pall achiev high-single-digit organ growth double-
digit growth biotech partli off-set soft microelectron segment margin
bp quarter includ bp underli expans look ahead life scienc
organ growth expect deceler due time larg pall
biotech industri equip order shift
diagnost organ revenu led double-digit growth radiomet
leica biosystem driven demand pull-in ahead new vat japan
went effect cepheid double-digit across major geographi
product line meanwhil beckman diagnost achiev fourth consecut quarter
mid-single-digit organ growth driven high growth market north america segment
margin bp report underli basi look ahead danah
expect strength radiomet leica biosystem moder due
japan vat impact result mid-single-digit diagnost organ growth
dental dental organ revenu declin though includ
bp impact discontinu certain product line geograph develop
market low-single-digit partli off-set china double-digit
specialti product technolog organ equip consum
due weaker demand across develop market manag expect
dental organ revenu low-single-digit due weaker equip
demand remind complet ipo dental busi
name envista ticker million net proce manag
primari rational separ dental view flexibl organ
inorgan invest includ stand-alone compani
environment appli solut organ growth unexpectedli deceler
larg due declin product id videojet report low-single-digit organ
declin tough y/i comp nearli growth partli off-set low-
single-digit growth packag busi meanwhil water qualiti maintain mid-
single-digit organ growth despit tough y/i comp double-digit trojan organ
revenu double-digit led north america hach low-single-digit
strength europ north america off-set declin china final chemtreat
mid-single-digit driven strength oil ga food beverag
detail ge
pleas see
report
septemb
announc ge
biopharma would
cytiva
upcom catalyst point monitor
acquir billion reason ev/ebitda multipl feb-
announc acquir ge life scienc biopharma busi cash
purchas price billion includ billion tax benefit net purchas price
roughli billion impli reason deal multipl price/sal
ev/ebitda surpris announc alway view danah
natur buyer busi given complementari natur
portfolio ge biopharma manag stand-alone oper compani within
life scienc segment rebrand cytiva billion purchas price
fund mixtur cash hand new debt issuanc billion equiti offer
complet compani expect credit rate downgrad
still-invest grade bbb follow deal addit deal expect produc
million annual cost save year-thre along potenti revenu synergi
though manag yet size opportun accret previous
estim deal gener cash ep would doubl
year-fiv impli high-single-digit said note estim
like impact lower-than-expect financ cost recent announc
small life scienc divestitur made help secur anti-trust approv final deal
expect complet time-frame push slightli
ge biopharma lead player bioprocess workflow grow organ
ge biopharma lead provid instrument consum softwar
support research discoveri process develop manufactur workflow
biopharmaceut drug busi expect gener annual revenu
billion ebitda margin equat billion annual ebitda
annual free cash flow also roughli billion addit revenu mix roughli
consum equip manag expect achiev
organ revenu growth thank secular driver across biolog drug develop cell
gene therapi demand high growth market key product line within
busi includ downstream bioprocess revenu mix upstream
bioprocess
divest small life scienc busi million help obtain regulatori approv
deal announc sell sever life scienc
busi sartoriu ag roughli million help obtain anti-trust regulatori approv
acquisit ge biopharma busi gener combin revenu
million life scienc mix includ label-fre biomolecular character
includ fortebio busi chromatographi hardwar resin includ pall process
chromatographi busi microcarri particl valid standard busi
complet divestitur sartoriu ag condit upon complet
danah acquisit though compani state none action
receiv regulatori approv yet would character asset sale part
routin anti-trust concess disclos chosen result
construct discuss differ intern regulatori bodi estim
life scienc divestitur would roughli dilut cash ep vs ge
biopharma deal accret
like pursu orderli stage exit remain ownership dental
complet ipo dental busi name envista ticker
million net proce manag primari rational separ dental
view flexibl organ inorgan invest includ
stand-alone compani recal argument led compani
spin-off industri busi expect exit remain
ownership envista either futur spin secondari offer
believ could eventu pursu spin-out water qualiti follow
complet ge biopharma acquisit stage exit dental believ
begin orchestr separ best-in-class qualiti platform either
stand-alone busi pair product id billion revenu
portfolio compris market-lead water test/analyt brand hach
segment mix chemic disinfect brand chemtreat ultraviolet disinfect
brand trojan filtrat brand pall water see water qualiti
leagu within global water sector recur revenu mix
company-averag profit solid mid-single-digit organ growth runway
market share gain db implement commerci execut new product
innov busi sit squar high-end water technolog continuum
command higher valuat barrier entri margin growth given scarciti
invest water pure-play market today believ publicli trade water
qualiti would tremend appeal investor
rel price-to-earnings trade near high-end rel rang share
current trade premium multi-industri sector report ep
cash ep believ stock trade premium target
group multipl high-end histor rel rang impli
price target support sector perform rate
ev/ebitda premium ev/ebitda basi trade
estim repres rel premium multi-industri peer group averag
surpris premium group given outsiz a-driven
amort premium price-to-earnings
share price trade premium weight averag price-to-earnings
publicly-trad peer report ep cash ep believ
deserv premium reflect market leadership db toolkit
price assum after-tax cost capit beta annual sale growth
termin growth rate
compani report capit market estim
millionsmarjunsepdecmar-ajun-asep-adecmarjunsepdecmarjunsepdecseg revenueslif environment appli total revenu organ revenu sale gener incomelif appli expens oper interest expens incom intang per share tool jvminor earn per share earn per share outstand outstand analysi gross oper pre-tax net incom sale sell gener research tax new pension account corpor expens exhibit danah annual incom statement
compani report capit market estim
revenueslif appli revenu sale gener incomelif appli expens oper income/expense- net interest intang per share earn tool jvminor earn per share earn per share outstand outstand analysi gross oper pre-tax net incom sale sell gener research tax asdiscontinu oper electr equip multi-industri
given portfolio migrat toward higher-tech life scienc busi believ
re-rat higher toward target rel price-to-earnings premium rang
believ trade high-end rang due solid
outlook investor enthusiasm pend acquisit
premium target group multipl price-to-earnings adjust ep
cash ep impli valuat support sector perform rate
risk rate price target
acquisit one acquisit compani sector alway risk
overpay experienc integr difficulti major deal believ
integr stumbl would damag investor trust leadership
organ growth acquisition-focus busi model investor often hone
organ revenu growth metric perceiv miss often
disproportion effect stock earn
econom condit macro trend inflat currenc credit avail suppli
chain materi cost could caus result lower forecast
financi risk disrupt global credit market could caus sale
earn estim optimist
margin sinc gener among highest gross margin sector
degre execut risk would see shortfal profit
regulatori chang govern regul us intern could
neg impact compani especi elev
beneficiari increas regul water product mark
manag success oper histori execut legendari
db framework seen manag talent period poach
industri compani time exodu talent could affect oper
manufactur market profession medic industri commerci
product servic facil locat across countri compani oper
four segment life scienc diagnost dental environment appli solut
also oper differenti framework growth lean leadership tool
process known danah busi system across aspect oper includ
product develop qualiti control global sourc sale market danah
modestli headquart washington employ peopl global
